A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays

Abstract

This panel of breast cancer xenografts includes 15 triple-negative, one ER positive and 2 ERBB2 positive. This panel represents a useful preclinical tool for testing new agents and protocols and for further exploration of the biological basis of drug responses.